<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920221-0115</DOCNO><DOCID>920221-0115.</DOCID><HL>   OTC Focus:   Index Advances 1.58% in Broad Rally;   Technology, Health Care Issues Rebound   ----   By Dave Pettit   Staff Reporter of The Wall Street Journal</HL><DATE>02/21/92</DATE><SO>WALL STREET JOURNAL (J), PAGE C6</SO><CO>   SB WNEWS</CO><MS>FINANCIAL (FIN)</MS><IN>STOCK INDEXES (NDX)OTC GENERAL MARKET COMMENT (OTC)SECURITIES (SCR)STOCK MARKET, OFFERINGS (STK)U.S. STOCK MARKET STATISTICS (STT)</IN><NS>STOCK AND OTHER INDEXES (NDX)PERSONNEL ANNOUNCEMENTS, PROMOTIONS, APPOINTMENTS (PER)STOCK andamp; OTHER MARKET NEWS (STK)</NS><RE>NORTH AMERICA (NME)NEW YORK (NY)UNITED STATES (US)</RE><LP>   NEW YORK -- Over-the-counter stocks recovered from twodays of stumbling and sprinted higher yesterday.   Traders said stocks in a broad range of industry groupsadvanced, sparked by renewed buying in segments that led themarket rally last year -- technology and health care. Bothsegments have faltered recently.</LP><TEXT>   &quot;Some of these areas were oversold,&quot; said Robert O'TooleSr., head of Nasdaq institutional sales at Lehman Brothers.&quot;People saw a little correction, and they are back buyingagain,&quot; he said.   Shares of software concern Microsoft, which fell a totalof 3 3/8 Tuesday and Wednesday, jumped 2 3/8 to 117 1/2.Medical Care International, a surgery center operator, gained2 3/4 to 70, after losing 4 1/2 points earlier this week.   The Nasdaq Composite Index, which tumbled 14 points duringthe prior two sessions, rocketed 9.82, or 1.58%, to 632.23.The Nasdaq 100 Index, which tracks large industrial stocks,soared 14.55, or 2.15%.   Advancing issues outpaced decliners by a wide 1,398 to877. Trading activity remained strong. National Market Systemvolume was 201,960,000 shares, just below Wednesday's205,790,000.   The Nasdaq Composite remains 12.69, or nearly 2%, belowits record of 644.92, which was set Feb. 12.   Traders said early OTC gains drew more buying later in thesession. &quot;No one wants to buy when {stocks} are going down,and everybody wants to buy when they are going up,&quot; saidSteve Bliss, head of OTC trading at Mabon Securities Corp. Hesaid he saw active trading among institutional investors.   &quot;If you are caught out there with cash, you look sillybecause what are you going to do with it?&quot; said LehmanBrothers' Mr. O'Toole. Even though long-term interest rateshave drifted somewhat higher recently, he said that overall,yields on interest-bearing investments remain unattractive.   Amgen, Nasdaq's largest biotechnology stock, rose 1 1/2 to64 1/2, while Liposome Technology jumped 3 to 21 3/4. Thecompanies will do research into using Amgen's proteintechnology and Liposome's &quot;stealth&quot; liposomes in developingtherapeutic products. The medical technology concernswouldn't disclose the ailments at which the treatments couldbe targeted.   Liposome Chairman Nick Arvanitidis contends the company'sstealth liposomes are able to remain intact in the body for alonger period than do traditional liposomes. Drugs are to beplaced in liposome shells to better target their delivery inthe body. Liposomes are made up of fatty molecules.   Neorx also advanced after entering a research agreementwith a larger medical technology company. Neorx rose 1/2 to 43/4 after it and Genentech entered a pact under which theywill work to develop treatments for breast and ovariancancer. In New York Stock Exchange composite trading,Genentech rose 1/2 to 27 3/4.   Sun Microsystems jumped 1 1/4 to 33 1/2. Some observersattributed the advance to anticipation about a conferencepresentation the company was scheduled to make yesterdayafternoon regarding its new Supersparc microchip. Others saidthe computer workstation concern's stock may have gainedfollowing Hewlett-Packard's higher-than-expected earningsreport Wednesday, Dow Jones Professional Investor Reportsaid.   H-P rose 3 1/8 to 76 5/8 in Big Board trading yesterday.Strong workstation sales helped to boost H-P's results.   Tseng Labs slumped 2 1/4 to 16 despite the company'sreport that fourth-quarter earnings reached 14 cents a share,up from 12 cents a share a year ago, and in line withanalysts' expectations. Mark Karsch, its chief financialofficer, said he wasn't aware of any news that would accountfor the price decline. &quot;I believe someone may have beenexpecting an earnings release in excess of what the marketwas expecting,&quot; he said. The stock jumped 1 1/2 Wednesday toa 52-week high.   Mr. Karsch, meanwhile, said he is comfortable withanalysts' estimates that put the company's first-quarter netat 18 cents to 19 cents a share on revenue of $19 million to$20 million. In the year-ago first quarter, the Newtown, Pa.,maker of video graphics computer chips had net of 16 cents ashare on revenue of $17 million. Mr. Karsch said Tseng isbenefiting from strong sales of its ET4000 video chip.   Autodesk rose 1 1/2 to 25. After the market closed, thesoftware developer reported fourth-quarter net income of 38cents a share, down from 53 cents a share a year earlier. Themean estimate of analysts surveyed by First Call, a unit ofThomson Financial Networks, was 41 cents a share for thelatest quarter.   Gull Laboratories fell 1 3/4 to 4 1/2 after the companyposted a loss of three cents a share for the fourth quarter,wider than a year-ago deficit of two cents a share. Itattributed the lower results to inventory adjustments andlosses in its natural products division. The Salt Lake Citycompany makes medical diagnostic products.   ---   SALOMON UPDATE: Patrick Davis, 35 years old, formerly asenior OTC trader with UBS Securities Inc., was named vicepresident and manager of OTC trading for Salomon BrothersInc. Mr. Davis fills a new position created after severalsenior OTC traders resigned from the troubled firm, which hasbeen cutting compensation in its trading operations in thewake of its Treasury-auction bidding scandal.</TEXT></DOC>